AVAC Statement Supporting R&D Tax Credits

The AIDS Vaccine Advocacy Coalition (AVAC) strongly supports a pre-clinical and clinical research and development (R&D) tax credit for work related to developing vaccines and microbicides for malaria, TB, and HIV/AIDS. An R&D tax credit would help pharmaceutical and biotech vaccine companies dedicate more resources to research and development on desperately needed vaccines and microbicides. In addition, this tax credit will provide a further incentive for drug manufacturers to undertake research on new vaccine candidates and accelerate their development.

AVAC's support for the pre-clinical and clinical R&D credits should not come at the expense of access to therapeutics.

Founded in 1995, AVAC is a coalition of volunteer advocates located throughout the country. In all of the work that we do, AVAC seeks to provide a well-informed, independent, and honest critique of current efforts by the U.S. government, the pharmaceutical and biotechnology industry, and other sectors toward developing an HIV vaccine. Our goal is to speed development of HIV vaccines without taking resources away from basic HIV research, drug development, or other prevention research.